Q: What do you see for potential in mdna? Biotechnology companies in canada are slim. It's this a company to own as part of a biotechnology basket?
5i Research Answer:
MDNA is interesting and its recent update provided that its MDNA11 preclinical data was promising. It does not have revenue or earnings and will likely continue to burn cash for the next few years. Analysts forecast it will start generating revenues in 2027. It does have $30M in cash on the balance sheet right now which is a positive. Dilluton and size are other risks here while it is overall a very speculative company. Initial trials have been positive but the risks are too high for us to endorse it right now.